Hello, everyone. How are you today? We are motoring along here on the Pharmalot corporate campus, where the heat has lifted and the birds are singing our song. Just the same, another busy day lies ahead. Your schedules, no doubt, are equally daunting. So please join us for the mandatory cup of stimulation and a bit of news of the world. Dig in and have a great day...
Biogen To Hire George Scangos As CEO (Bloomberg News)
Celegene To Buy Abraxis For $2.9 Billion (Associated Press)
Pfizer Gets Incentives To Stay In Virginia (Richmond Times-Dispatch)
Sanofi-Aventis Pays $75M For TargeGen (Bloomberg News)
A Fix For The Avandia Mess (Forbes)
Genzyme Expects More Cerezyme, Fabrazyme Shortages (Reuters)
Sanofi-Aventis To Build New Plant In Saudi Arabia (InPharma-Technologist)
Bristol-Myers Converts Old Plant For Biologics (Syracuse Post-Standard)
Sanofi's Zentiva CEO To Step Down (Dow Jones)
Merck KGgA Expects MS Pill To Lift Margins (Reuters)
Bayers Drops One Patent Case Against Teva Over Yaz (Reuters)
Oriole thx to g-graphic flickr creative commons
1 Comment
Based on recent history, any locale that offers Pfizer any sort of financial incentives not to leave is most certainly running a fool's errand.